Intravitreal injections of ICON-1 in eyes with neovascular age-related macular degeneration were found to be safe and well-tolerated in doses up to 300 µg.
The open-label, interventional, dose-escalation phase 1 trial included 18 patients with choroidal neovascularization due to neovascular AMD. Each dose cohort included six patients, with patients receiving a single intravitreal injection of ICON-1 (Iconic Therapeutics) at doses of 60 µg, 150 µg or 300 µg.
“This is the first clinical report of a novel mechanism in the treatment of neovascular AMD, distinct from
Uncategorized